EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

TP53 mutations and TET2 deficiency cooperate to drive leukemogenesis and establish an immunosuppressive environment

Pu Zhang, Ethan C Whipp, Sarah J Skuli, Mehdi Gharghabi, Caner Saygin, Steven A Sher, Martin Carroll, Xiangyu Pan, Eric D Eisenmann, Tzung-Huei Lai, Bonnie K Harrington, Wing Keung Chan und 31 weitere

Journal of Clinical Investigation · 15.05.2025 · 135 (10)

DOI: 10.1172/jci184021 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 20.03.2025. Verfasst von Pu Zhang und 42 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA. Hauptthemen laut MEDLINE: Tumor Suppressor Protein p53, DNA-Binding Proteins, Proto-Oncogene Proteins, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NHLBI NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mutations and deletions in TP53 are associated with adverse outcomes in patients with myeloid malignancies, and there is an urgent need for the development of improved therapies for TP53 -mutant leukemias. Here, we identified mutations in TET2 as the most common co-occurring mutation in patients with TP53- mutant acute myeloid leukemia (AML). In mice, combined hematopoietic-specific deletion of TET2 and TP53 resulted in enhanced self-renewal compared with deletion of either gene alone. Tp53/Tet2 double-KO mice developed serially transplantable AML. Both mice and patients with AML with combined TET2/TP53 alterations upregulated innate immune signaling in malignant granulocyte-monocyte progenitors, which had leukemia-initiating capacity. A20 governs the leukemic maintenance by triggering aberrant noncanonical NF-κB signaling. Mice with Tp53/Tet2 loss had expansion of monocytic myeloid-derived suppressor cells (MDSCs), which impaired T cell proliferation and activation. Moreover, mice and patients with AML with combined TP53/TET2 alterations displayed increased expression of the TIGIT ligand, CD155, on malignant cells. TIGIT-blocking antibodies augmented NK cell–mediated killing of Tp53/Tet2 double-mutant AML cells, reduced leukemic burden, and prolonged survival in Tp53/Tet2 double-KO mice. These findings describe a leukemia-promoting link between TET2 and TP53 mutations and highlight therapeutic strategies to overcome the immunosuppressive bone marrow environment in this adverse subtype of AML.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor Suppressor Protein p53DNA-Binding ProteinsProto-Oncogene ProteinsLeukemia, Myeloid, AcuteMutationAnimalsDioxygenasesMiceHumansMice, KnockoutMyeloid-Derived Suppressor CellsKiller Cells, NaturalFemale

Stichwörter der Autor:innen

HematologyInflammationLeukemiasMouse modelsOncologyp53

Substanzen

DioxygenasesTumor Suppressor Protein p53DNA-Binding ProteinsProto-Oncogene ProteinsTet2 protein, mouseTET2 protein, humanTrp53 protein, mouseTP53 protein, human

Autor:innen und Institutionen

  • Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA.
  • Molecular Pharmacology Program, Sloan Kettering Institute, New York, New York, USA.
  • Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio, USA.
  • University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Section of Hematology/Oncology, University of Chicago, Chicago, Illinois, USA.
  • Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine, New York, New York, USA.

Förderung

  • NIDDK NIH HHS
  • NHLBI NIH HHS
  • NCI NIH HHS
  • National Cancer Institute
  • NHLBI Division of Intramural Research
  • Damon Runyon Cancer Research Foundation
  • Leukemia and Lymphoma Society
  • Edward P. Evans Foundation

Zitieren

APA

Zhang, P., Whipp, E. C., Skuli, S. J., Gharghabi, M., Saygin, C., Sher, S. A., Carroll, M., Pan, X., Eisenmann, E. D., Lai, T. H., Harrington, B. K., Chan, W. K., Youssef, Y., Chen, B., Penson, A., Lewis, A. M., Castro, C. R., Fox, N., Cihan, A., …, & Lapalombella, R. (2025). TP53 mutations and TET2 deficiency cooperate to drive leukemogenesis and establish an immunosuppressive environment. Journal of Clinical Investigation, 135(10). https://doi.org/10.1172/jci184021

Vancouver

Zhang P, Whipp EC, Skuli SJ, Gharghabi M, Saygin C, Sher SA, et al. TP53 mutations and TET2 deficiency cooperate to drive leukemogenesis and establish an immunosuppressive environment. Journal of Clinical Investigation. 2025;135(10). doi:10.1172/jci184021

BibTeX
@article{Zhang2025,
  author = {Zhang, Pu and Whipp, Ethan C and Skuli, Sarah J and Gharghabi, Mehdi and Saygin, Caner and Sher, Steven A and Carroll, Martin and Pan, Xiangyu and Eisenmann, Eric D and Lai, Tzung-Huei and Harrington, Bonnie K and Chan, Wing Keung and Youssef, Youssef and Chen, Bingyi and Penson, Alex and Lewis, Alexander M and Castro, Cynthia R and Fox, Nina and Cihan, Ali and Le Luduec, Jean-Benoit and DeWolf, Susan and Kauffman, Tierney and Mims, Alice S and Canfield, Daniel and Phillips, Hannah and Williams, Katie E and Shaffer, Jami and Lozanski, Arletta and Doong, Tzyy-Jye and Lozanski, Gerard and Mao, Charlene and Walker, Christopher J and Blachly, James S and Daniyan, Anthony F and Alinari, Lapo and Baiocchi, Robert A and Yang, Yiping and Grieselhuber, Nicole R and Campbell, Moray J and Baker, Sharyn D and Blaser, Bradley W and Abdel-Wahab, Omar and Lapalombella, Rosa},
  title = {TP53 mutations and TET2 deficiency cooperate to drive leukemogenesis and establish an immunosuppressive environment},
  journal = {Journal of Clinical Investigation},
  year = {2025},
  volume = {135},
  number = {10},
  doi = {10.1172/jci184021}
}
Kostenlos starten →